Navigation Links
Takeda to Acquire Nycomed
Date:5/18/2011

p>Tokyo (JST)

9:00 am

2:00 pm

9:00 pm

9:00 pm

10:00 pm

(May 19)

(May 19)

(May 19)

(May 19)

(May 19)Approx. Duration

60 MinutesToll-free Dial-in

Australia

Belgium

Canada

France

Germany

Hong Kong

Japan

Singapore

U.K.

U.S.A

1-800-035-017

0800-71662

1-877-855-5648

080-090-4503

0800-1802125

800-933-206

0120-917-642

800-101-1716

0800-404-9212

1-877-887-6076Direct Dial-in

Japan : +81-3-4570-1820Pass code

421299#You can also listen to the conference call via internet as following URL. (Listen only)
http://www.takeda.com/investor-information/presentations-events/index_2576.html

The conference call recording of event will be available on Takeda's website at http://www.takeda.com within several days.

About TakedaLocated in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for patients worldwide through leading innovation in medicine. Additional information about Takeda is available through its corporate website, www.Takeda.com.

About NycomedNycomed is a privately owned global pharmaceutical company with a diversified portfolio focused on branded medicines in gastroenterology, respiratory and inflammatory diseases, pain, osteoporosis and tissue management. A range of OTC products completes the portfolio. Its R&D is structured around collaborations. In-licensing and expanding in emerging markets are cornerstones of the company's growth strategy. Nycomed emp
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Takeda Submits New Drug Application for Alogliptin (SYR-322) in the U.S.
2. Takeda Doses First Patient in a U.S. Phase 1 Study of Hematide(TM) to Treat Chemotherapy Induced Anemia
3. Takeda Submits a New Drug Application in the U.S. for Alogliptin (SYR-322) / ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
4. Takedas Investigational PPI TAK-390MR Demonstrated Higher Healing Rates Compared to Lansoprazole as the Severity of Erosive Esophagitis Grade Increased, a New Integrated Analysis Showed
5. Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
6. Takeda Initiates Two Phase III Studies with Vedolizumab (MLN0002) in Patients with Inflammatory Bowel Disease
7. Takeda to Revise Timing of Alogliptin and Alogliptin/ACTOS MAA Filings in Europe
8. Takeda Receives FDA Complete Response Letter for Alogliptin, an Investigational Treatment for Type 2 Diabetes
9. Takeda Provides Update on the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl)
10. Takeda Initiates Cardiovascular Outcomes Trial for Alogliptin, An Investigational Treatment for Type 2 Diabetes
11. Takeda Receives FDA Complete Response Letter for the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 23, 2015  Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), announced that ... of Lixte,s lead compound, LB‑100, is being conducted, has been ... S. Kovach , M.D., the founder and President of Lixte, ... at a single site. Accrual of patients, however, was slower ...
(Date:1/23/2015)... 23, 2015  CytoSorbents Corporation (NASDAQ CM: CTSO), a ... cytokine adsorber to reduce deadly inflammation in critically-ill ... $385,642, net of transaction costs, in non-dilutive funding ... Tax Certificate Transfer Program sponsored by the New ...
(Date:1/23/2015)... and BOSTON , January 23, ... drug discovery and development company, is delighted to announce that ... been awarded to Miles Congreve (Vice President of ... and Malcolm Weir (Chief Executive Officer and co-founder) ...
Breaking Medicine Technology:Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 2Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 4
... Dr. Joan Fallon , founder and CEO of Curemark, ... on the treatment of neurological diseases, presented at the Keystone Symposia meeting, ... in Snowbird, Utah .   , ... Fallon presented on "The Role of Protein Assimilation and Utilization ...
... SAN FRANCISCO , May 3 SARcode ... novel class of lymphocyte function-associated antigen-1 (LFA-1) antagonists, today ... study evaluating topical SAR 1118 ophthalmic solution ... sicca). The study results were presented at the Dry ...
Cached Medicine Technology:Dr. Joan Fallon, Curemark CEO, Addresses Keystone Symposia Meeting On Autism 2Dr. Joan Fallon, Curemark CEO, Addresses Keystone Symposia Meeting On Autism 3SARcode Corporation Announces Phase 2 Study Results of SAR 1118 Topical Ophthalmic Solution for the Treatment of Dry Eye 2SARcode Corporation Announces Phase 2 Study Results of SAR 1118 Topical Ophthalmic Solution for the Treatment of Dry Eye 3
(Date:1/22/2015)... Padre Murphy's and Owner Tom Boyle in Glendale, ... Health Alliance (PPHA). The PPHA's passion for others' well-being ... NFL greats, treated for obstructive sleep apnea (OSA) has propelled ... cause in the valley. The most recent plans for an ...
(Date:1/22/2015)... 2015 The Incredible Bulk is a revolutionary ... increase lean muscle by up to 30lbs in less than ... of HealthyandFitZone.com’s Stan Stevenson, prompting an investigative review. , “Our ... step-by-step, scientific diet formula that allows the body to pack ...
(Date:1/22/2015)... Minn. (PRWEB) January 22, 2015 Blue Cross ... those Minnesotans who exemplify what it means to “Live Fearless.” ... chance for people to share their stories about how they ... or simply inspired others by living in the moment. By ...
(Date:1/22/2015)... York, New York (PRWEB) January 22, 2015 ... http://www.vaginalmeshlawsuit2015.com/ ) in the U.S. District Court, Southern District of ... C.R. Bard, Inc. in that proceeding’s first bellwether trial. In ... request for a new trial after finding that C.R. Bard ...
(Date:1/22/2015)... Dallas, TX (PRWEB) January 22, 2015 ... the issue of experience and person-centeredness in the long-term ... moving towards action across the continuum. The paper, “The ... the Continuum,” engages perspectives and practices of the patient, ...
Breaking Medicine News(10 mins):Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3
... (Amex: ILI ), a company focusing on ... Lewis H. Bender, Chief Executive,Officer, will present at ... on January 30th at 11:45AM to be held ... In addition, Kenneth S. Kornman, DDS., Ph.D. ...
... for an End to ... NEW YORK, Jan. 28 Legal Momentum, in ... United States,(SIECUS) and the Center for Health and Gender ... 29) and at the University of,Southern Maine Portland campus ...
... is a Survivor,s Story of Overcoming ... Adversity and Giving of Oneself, WASHINGTON, Jan. 28 On ... was raped, beaten and held hostage,at gunpoint for two hours. In her ... victim:, "They took my money, my credit cards and my body. ...
... Extension in Europe for the Treatment of ... Patients with Metastatic Colorectal Cancer, BASEL, Switzerland, Jan. ... given its approval for the significantly,wider use of its anti-angiogenic ... new broader label will now allow Avastin to be used ...
... Local assisted living facility in violation of "Nicole,s Law" designed to ... protect ... at Atria Senior Living? That,s what members of the Campaign to ... Place facility at 15 Stevens Street in Andover was found in,violation ...
... in Western society are suffering from auto-immune diseases. Discovering ... important step in the search for targeted medicines. VIB ... Leuven joined forces and have elucidated the function of ... They are the first to show that MALT1 is ...
Cached Medicine News:Health News:Interleukin Genetics, Inc. Management to Present at Healthcare Conferences 2Health News:Harm of Abstinence-Only Programs in U.S. and Abroad Subject of Panel Discussion at Two Maine College Campuses 2Health News:Harm of Abstinence-Only Programs in U.S. and Abroad Subject of Panel Discussion at Two Maine College Campuses 3Health News:IF You Had Survived a Brutal Rape at Gunpoint, Would You Teach Aerobics to Convicted Felons? 2Health News:Many More Patients Can Now Benefit from Avastin's Proven Survival Benefits 2Health News:Many More Patients Can Now Benefit from Avastin's Proven Survival Benefits 3Health News:Activists Raise Alarm for Seniors, Deliver Carbon Monoxide Detectors to Atria Marland Place 2Health News:A major step toward a more targeted treatment for auto-immune diseases? 2
... The latest in Canons DR innovations, ... DR system. With a compact and lightweight ... positioned, just like conventional screen-film cassettes. It ... that are difficult to get with fixed ...
The Oscor PACE 101 H is an external single chamber cardiac demand pacemaker. The PACE 101 H feature an option for a atrial overdrive stimulation....
... Oscors proprietary quadripolar pacing wire ... pacing and sensing in the ... two bipolar wires in one ... the atrium and ventricle are ...
... 227 T is a quadripolar ... cardiac pacing and monitoring during ... TME 227 T features tines ... which allows safe and easy ...
Medicine Products: